Anyone who has invested their time in creating improved outcomes for patients becomes familiar with a kind of balancing act. You must be committed to the science and precision involved in diagnosis and therapy — the research, the development, the trials, the care plan. You must also be devoted to the art of the therapy — the patient’s well-being, the expectations, the lives impacted.

After all, the patients we care for are … people. And so, anyone who has invested time in creating actual, improved outcomes knows: it’s a balance.

Our guest on this episode of Rare Voices is an example of what happens when science meets art. He is a master at understanding how to balance what seem like two competing ideas. Dave Penake, CEO of Saol Therapeutics, combines his training as an engineer and systems designer with his passion for serving patients with rare and orphan diseases.

Previous to Saol, Dave served as Vice President, Commercial Operations at Corcept Therapeutics and held roles of increasing responsibility at Genentech. In addition to his experience in biotechnology and pharmaceuticals, Dave has designed and launched devices and has experience in a number of different technologies.

As you listen to our conversation, be prepared to be provoked by big questions, the kind that will check your balance and set you on a new course — one where you can really put the patient first.

Ver todos los episodios